AFFiRiS logo_white with blue globe.PNG
Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease to be presented at the 16th Annual Huntington's Disease Therapeutics Conference
27 avr. 2021 03h00 HE | AFFiRiS AG
Monoclonal antibody C6-17 designed to target mutant huntingtin protein (mtHTT) and to reduce spread of Huntington’s disease pathologyHuman mtHTT transgenic mice treated with mAB C6-17 showed...
retro.jpg
Retrotope Announces Completion of Enrollment in Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
21 avr. 2021 07h00 HE | Retrotope
LOS ALTOS, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
retro.jpg
Retrotope Announces Initiation of Phase 2 Study of RT001 in Patients with Amyotrophic Lateral Sclerosis (ALS)
17 mars 2021 07h00 HE | Retrotope
LOS ALTOS, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
retro.jpg
Retrotope to Present at H.C. Wainwright Global Life Sciences Conference
03 mars 2021 16h05 HE | Retrotope
LOS ALTOS, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
retro.jpg
Retrotope Granted Rare Pediatric Disease Designation from FDA for Lead Development Candidate, RT001, in Two Life-Threatening Neurodegenerative Indications
25 févr. 2021 07h00 HE | Retrotope
Company Currently Conducting Late-Stage Clinical Trials in Both Infantile Neuroaxonal Dystrophy (INAD) and Friedreich’s Ataxia (FA) RT001 also Granted Fast Track Designation by FDA in FA; Orphan Drug...
retro.jpg
Retrotope Appoints Rick E Winningham as Chairman of Board of Directors in Advance of Key Clinical Trial Data Readouts
11 févr. 2021 07h00 HE | Retrotope
LOS ALTOS, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Retrotope, a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class therapies for degenerative diseases,...
Emerald Health Pharmaceuticals’ Scientific Team Leads Cannabinoid Research Showing Potential to Impact Neurodegenerative Diseases
20 sept. 2017 07h00 HE | Emerald Health Pharmaceuticals Inc.
SAN DIEGO, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP), a development-stage company focused on treating life-threatening diseases through cannabinoid science, is...
Emerald Health Pharmaceuticals to Treat Life-Threatening Diseases with Novel Synthetic Cannabinoid-Derived Molecules
14 sept. 2017 09h00 HE | Emerald Health Pharmaceuticals Inc.
SAN DIEGO, Sept. 14, 2017 (GLOBE NEWSWIRE) -- Emerald Health Pharmaceuticals Inc. (EHP) today announced its mission to discover, develop and commercialize novel synthetic cannabinoid-derivative drug...
Elsevier Recognizes Alzheimer's - Brain Awareness Month with New Book, "A Roadmap for Curing Cancer, Alzheimer's, and Cardiovascular Disease"
06 juin 2017 04h00 HE | Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - June 06, 2017) - Elsevier, the information analytics company specializing in science and health, today announced A Roadmap for Curing Cancer, Alzheimer's, and...
Breakthrough: Paradigm Shift in Monitoring and Improving Brain Health
30 mai 2017 08h00 HE | Posit Science
SAN FRANCISCO, May 30, 2017 (GLOBE NEWSWIRE) -- Dr. Michael Merzenich will unveil a revolutionary approach to monitoring, maintaining and improving brain health at the world’s most prestigious...